Results of a survey of hospital coagulation laboratories in the United States, 2001

Archives of Pathology and Laboratory Medicine

Volumn 129, Issue 1, 2005, Pages 47-60

  Shahangian, Shahram ^a   Stanković, Ana K ^a,b   Lubin, Ira M ^a   Handsfield, James H ^a   White, Mark D ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b BD Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; CITRATE SODIUM; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

BLOOD CLOTTING TEST; CENTRIFUGATION; HOSPITAL LABORATORY; LABORATORY PERSONNEL; PARTIAL THROMBOPLASTIN TIME; PHLEBOTOMY; PRACTICE GUIDELINE; PROTHROMBIN TIME; QUALITY CONTROL; REVIEW; UNITED STATES;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; DATA COLLECTION; DRUG MONITORING; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITAL BED CAPACITY; HUMANS; LABORATORIES, HOSPITAL; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; QUESTIONNAIRES; REFERENCE VALUES; UNITED STATES;

EID: 11844255344     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Andrew M, Brigden M, Bormanis J, et al, for the Thrombosis Interest Group of Canada. INR reporting in Canadian medical laboratories. Am J Hematol. 1995;48:237-239.
2. Ansell JE. Imprecision of prothrombin time monitoring of oral anticoagulation: a survey of hospital laboratories. Am J Clin Pathol. 1992;98:237-239.
3. Brigden ML, Johnston MJ, for the Thrombosis Interest Group of Canada. INR reporting in Canadian medical laboratories: an update. Am J Clin Pathol. 1998; 109:589-594.
4. Brigden ML, Johnston M, for the Thrombosis Interest Group of Canada. A survey of aPTT reporting in Canadian medical laboratories: the need for increased standardization. Am J Clin Pathol. 2000;114:276-282.
5. Favaloro EJ, Smith J, Petinos P, Collecutt M, Street A, Hertzberg M, for the RCPA Quality Assurance Program in Haematology Scientific Haemostasis Advisory Panel. Laboratory testing, diagnosis, and management of von Willebrand disease: current practice in Australasia. Am J Clin Pathol. 1999;112:712-719.
6. Favaloro EJ, Smith J, Petinos P, Hertzberg M, Koutts J, for the RCPA Quality Assurance Program in Haematology Scientific Haemostasis Advisory Panel. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. Thromb Haemost. 1999;82:1276-1282.
7. Favaloro EJ, Thom J, Baker R. Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey. Blood Coagul Fibrinolysis. 2000;11;729-737.
8. Graves DF, Chernin JM, Kurusz M, Zwischenberger JB. Anticoagulation practices during neonatal extracorporeal membrane oxygenation: survey results. Perfusion. 1996;11:461-466.
9. Lum G. Critical limits (alert values) for physician notification: universal or medical center specific limits? Ann Clin Lab Sci. 1998;28:261-271.
10. Mackinlay N, Favaloro E, Arthur C, Smith J, Aboud M. A survey of heparin monitoring in Australasia. Pathology. 1996;28:343-347.
11. Murray ET, Fitzmaurice DA. An evaluation of quality control activity for near patient testing in primary care. Br J Gen Pract. 1998;48:1853-1854.
12. Yim JM, Albers GW, Vlasses PH. Anticoagulant therapy monitoring with international normalized ratio at US academic health centers. Ann Pharmacother. 1996;30:1390-1395.
13. Ansell JE, Buttaro ML, Thomas OV, Knowlton CH, for the Anticoagulation Guidelines Task Force. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Ann Pharmacother. 1997;31:604-615.
14. Brenner BR, Nowak-Gottl U, Kosch A, Manco-Johnson M, Laposata M. Diagnostic studies for thrombophilia in women on hormonal therapy and during pregnancy, and in children. Arch Pathol Lab Med. 2002;126:1296-1303.
15. Centers for Disease Control and Prevention. CLIA Subpart K-Quality Systems for Nonwaived Testing, Section 493.1255: Standard: calibration and calibration verification procedures. Available at: http://www.phppo.cdc.gov/ clia/regs/ subpart_k.aspx#493.1255. Accessed August 16, 2004.
16. Centers for Disease Control and Prevention. CLIA Subpart K-Quality Systems for Nonwaived Testing, Section 493.1269: Standard: hematology. Available at: http://www.phppo.cdc.gov/clia/regs/subpart_k.aspx#493.1269. Accessed August 16, 2004.
17. Centers for Disease Control and Prevention. CLIA Subpart K-Quality Systems for Nonwaived Testing, Section 493.1291: Standard: test report. Available at: http://www.phppo.cdc.gov/clia/regs/subpart_k.aspx#493.1291. Accessed August 16, 2004.
18. Chandler WL, Rodgers GM, Sprouse JT, Thompson AR. Elevated hemostatic factor levels as potential risk factors for thrombosis. Arch Pathol Lab Med. 2002;126:1405-1414.
19. Fairweather RB, Ansell J, van den Besselaar AM, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy. Arch Pathol Lab Med. 1998;122:768-781.
20. Goodwin AJ, Rosendaal FR, Kottke-Marchant K, Bovill EG. A review of the technical, diagnostic, and epidemiologic considerations for protein S assays. Arch Pathol Lab Med. 2002;126:1349-1366.
21. Kottke-Marchant K, Comp P. Laboratory issues in diagnosing abnormalities of protein C, thrombomodu/in, and endothelial cell protein C receptor. Arch Pathol Lab Med. 2002;126:1337-1348.
22. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med. 1998;122:799-807.
23. NCCLS. Collection, Transport and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays: Approved Guideline. 3rd ed. Wayne, Pa: NCCLS; 1998. Document H21-A3.
24. Nelson DE. Current considerations in the use of the APTT in monitoring unfractionated heparin. Clin Lab Sci. 1999;12:359-364.
25. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122:782-798.
26. Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of factorV Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med. 2002;126:1304-1318.
27. Triplett DA. Antiphospholipid antibodies. Arch Pathol Lab Med. 2002;126:1424-1429.
28. Van Cott EM, Laposata M, Prins MH. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Arch Pathol Lab Med. 2002;126:1281-1295.
29. Committee on Quality of Health Care in America, Institute of Medicine. To Err Is Human: Building a Safer Health System. Washington, DC: National Academy Press; 2000.
30. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med. 2000;160:1612-1617.
31. Reddy NM, Hall SW, MacKintosh FR. Partial thromboplastin time: prediction of adverse events and poor prognosis by low abnormal values. Arch Intern Med. 1999;159:2706-2710.
32. Steindel SJ, Rauch WJ, Simon MK, Handsfield J. National Inventory of Clinical Laboratory Testing Services (NICLTS): development and test distribution for 1996. Arch Pathol Lab Med. 2000;124:1201-1208.
33. Adcock DM, Kressin DC, Marlar RA. Minimum specimen volume requirements for routine coagulation testing: dependence on citrate concentration. Am J Clin Pathol. 1998;109:595-599.
34. Reneke J, Etzell J, Leslie S, Ng VL, Gottfried EL. Prolonged prothrombin time and activated partial thromboplastin time due to underfilled specimen tubes with 109 mmol/L (3.2%) citrate anticoagulant. Am J Clin Pathol. 1998;109:754-757.
35. Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol. 1997;107:105-110.
36. Bussey HI, Force RW, Bianco TM, Leonard AD. Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy. Arch Intern Med. 1992;152:278-282.
37. Moriarty HT, Lam-Po-Tang PR, Anastas N. Comparison of thromboplastins using the ISI and INR system. Pathology. 1990;22:71-76.
38. NCCLS. How to Define and Determine Reference Intervals in the Clinical Laboratory: Approved Guideline. 2nd ed. Wayne, Pa: NCCLS; 2000. Document C28-A2.
39. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1995;108(suppl 4):231S-246S.
40. Kitchen S, Jennings I, Woods TA, Preston FE. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol. 1996;49:10-14.
41. Adcock D, Kressin D, Marlar RA. The effect of time and temperature variables on routine coagulation tests. Blood Coagul Fibrinolysis. 1998;9:463-470.
42. Shojania AM, Tetreault J, Turnbull C. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer. Am J Clin Pathol. 1988;89:19-23.
43. Davis KD, Danielson CF, May LS, Han ZQ. Use of different thromboplastin reagents causes greater variability in international normalized ratio results than prolonged room temperature storage of specimens. Arch Pathol Lab Med. 1998;122:972-977.
44. Scialla SJ. Heparin monitoring by activated partial thromboplastin time: comparison of ex vivo measurement and in vitro standardization. Am J Clin Pathol. 1985;84:351-354.
45. College of American Pathologists. Comprehensive Coagulation Survey: Participant Summary (Set CG2-A). Northfield, Ill: College of American Pathologists; 1995.
46. Smythe MA, Koerber JM, Westley SJ, et al. Use of the activated partial thromboplastin time for heparin monitoring. Am J Clin Pathol. 2001;115:148-155.
47. Souto JC, Almasy L, Muniz-Diaz E, et al. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol. 2000;20:2024-2028.
48. Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ. Type 1 von Willebrand disease: a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol. 2000;108:259-264.
49. Hooper WC, Evatt BL. The role of activated protein C resistance in the pathogenesis of venous thrombosis. Am J Med Sci. 1998;316:120-128.
50. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med. 2001;3:139-148.
51. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med. 1999;130:643-650.
52. Hille ET, Westendorp RG, Vandenbroucke JP, Rosendaal FR. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood. 1997;89:1963-1967.
53. Sage-el A, Burns E, Wenz B. The unwarranted use of replicate analysis in routine coagulation studies. Am J Clin Pathol. 1985;83:81-83.
54. Kramer G, Bradlow BA. An analysis of duplicate testing of prothrombin time and activated partial thromboplastin time assays. Am J Clin Pathol. 1991;95:77-81.
55. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158:1641-1647.
56. O'Connor AM, Boyd NF, Tritchler DL, Kriukov Y, Sutherland H, Till JE. Eliciting preferences for alternative cancer drug treatments: the influence of framing, medium, and rater variables. Med Decis Making. 1985;5:453-463.
57. Perrin BM, Barnett BJ, Walrath L, Grossman JD. Information order and outcome framing: an assessment of judgment bias in a naturalistic decision-making context. Hum Factors. 2001;43:227-238.